For years the answer was a flat no. Medicare would not pay for a GLP-1 medication prescribed solely for weight loss, no matter how high the sticker price. That changed on July 1, 2026, when a temporary federal program called the Medicare GLP-1 Bridge began covering certain GLP-1 drugs for chronic weight management. This guide explains what Medicare now covers, who qualifies, why Ozempic is left out, and what your options are if you do not qualify.
Quick Answer
Traditional Medicare Part D does NOT cover GLP-1 medications used solely for weight loss, because of a statutory exclusion in place since 2003. However, starting July 1, 2026, the temporary Medicare GLP-1 Bridge program covers Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo (tablet) for chronic weight management at a $50 monthly copay, if you qualify. Ozempic is not covered for weight loss and is not part of the Bridge program, though Part D usually covers it for type 2 diabetes. Medicare does not cover compounded GLP-1 medications at all. If you do not qualify for the Bridge program, compounded semaglutide or tirzepatide through a US-licensed telehealth provider is a cash-pay option outside Medicare, priced independently by each provider. Compounded medications are not FDA-approved as final products.
This article is educational and is not medical advice. Medicare rules are complex and depend on your specific plan. Confirm coverage details with Medicare.gov or your Part D plan. Individual results vary.
The history: why Medicare said no for so long
Medicare Part D has long operated under a statutory exclusion that bars coverage of drugs used for "weight gain or weight loss." That language comes from the Medicare Modernization Act of 2003, written in an era when weight-loss drugs were viewed very differently from today's GLP-1 medications. Because of that exclusion, even as semaglutide and tirzepatide transformed obesity care, Medicare could not pay for them when the only indication was weight management.
That is the backdrop for the 2026 change. The exclusion still exists. The GLP-1 Bridge is a temporary workaround layered on top of it, not a repeal.
What changed on July 1, 2026: the Medicare GLP-1 Bridge
The Medicare GLP-1 Bridge is a temporary federal demonstration program that started July 1, 2026 and is scheduled to run through December 31, 2027. It is available nationwide to eligible people with Medicare drug coverage, whether through a standalone Medicare drug plan or a Medicare health plan that includes drug coverage. Per the Medicare.gov fact sheet, you are not eligible if your only Medicare coverage is through certain special plan types, such as private fee-for-service plans, cost contract plans, or a PACE organization.
Under the Bridge program, per the Medicare.gov fact sheet (June 2026):
| Feature | Detail |
|---|---|
| Covered drugs | Wegovy (injection or tablet), Zepbound (KwikPen only), Foundayo (tablet) |
| Not covered | Ozempic (for weight loss), single-dose Zepbound pens and Zepbound vials, compounded GLP-1 |
| Monthly copay | $50 regardless of income level |
| Copay toward deductible or out-of-pocket max | No |
| Medicare Prescription Payment Plan | These drugs are not eligible for it |
| Program window | July 1, 2026 through December 31, 2027 |
| Approval | Your doctor submits a form to Medicare; refills need no new approval while you stay on the same drug, even if the dose changes |
The $50 copay is the headline. For a category where the cash list price runs over $1,000 a month, a fixed $50 copay is a dramatic change for those who qualify.
Who qualifies for the Bridge program
Eligibility is specific, and the list below mirrors the Medicare.gov fact sheet (CMS product 12234) rather than a paraphrase. You must meet all four requirements:
- You have Medicare Part D drug coverage, through a standalone Medicare drug plan or a Medicare health plan that includes drug coverage. You are not eligible if your only coverage is through certain special plan types, such as private fee-for-service plans, cost contract plans, or a PACE organization.
- You are not already eligible to receive a GLP-1 drug through your Medicare drug plan. If your plan has been paying for a GLP-1 for any reason, you keep getting it through the plan, not the Bridge.
- You do not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. For those conditions, your plan may already cover a GLP-1 under its normal rules.
- You are at least 18 and at least one of these is true:
- your BMI is 35 or higher;
- your BMI is 30 or higher and you have certain types of heart failure, high blood pressure that is hard to control, or chronic kidney disease at stage 3a or above;
- your BMI is 27 or higher and you have prediabetes, or you have had a heart attack, stroke, or blocked arteries in your legs or arms.
Your doctor sends the prescription, and after the pharmacy confirms eligibility, submits a form to get approval from Medicare. Medicare then mails you a letter confirming your medicine is covered. Refills do not need a new approval as long as you stay on the same drug, even if your dose changes.
Not sure of your BMI? Use our free BMI calculator to see where you land before you talk to your provider.
Why Ozempic is excluded
This surprises a lot of people. Ozempic is one of the most recognized GLP-1 names, yet it is not part of the Bridge program. The reason is that Ozempic is FDA-approved for type 2 diabetes, not for weight management. The Bridge program is specifically a weight-management benefit, so it covers the drugs approved for chronic weight management (Wegovy and Zepbound) rather than the diabetes-indicated products.
If you have type 2 diabetes, that is a different door: Medicare Part D generally covers Ozempic or Mounjaro for diabetes, subject to your plan's formulary and prior-authorization rules. But if your goal is weight loss and you do not have diabetes, Ozempic is not the Medicare route.
What Medicare still does not cover
Three gaps remain even after the 2026 change:
1. Weight-loss use outside the Bridge program. The underlying statutory exclusion is intact. Outside the temporary Bridge demonstration, Part D still will not pay for a GLP-1 used solely for weight loss.
2. Ozempic and Mounjaro for weight loss. Covered for diabetes, not for weight management.
3. Compounded GLP-1 medications. Medicare does not cover compounded semaglutide or tirzepatide. Compounded preparations are not FDA-approved final products and sit outside Part D formularies. The Bridge program covers only the specific brand-name products it names.
If you do not qualify: your options
Plenty of people will not fit the Bridge criteria, will not want to wait out a prior authorization, or will want a medication Medicare does not cover for weight loss. Here are the honest alternatives.
Check for a covered indication. If you have type 2 diabetes or established cardiovascular disease, ask your provider whether a covered indication applies. Wegovy, for example, may be covered to reduce cardiovascular risk in people with established heart disease, separate from the Bridge program.
Manufacturer cash programs. Novo Nordisk and Eli Lilly run cash-pay pharmacy channels for their brand-name products that can lower the price versus full retail for people paying out of pocket.
Compounded GLP-1 through licensed telehealth. Compounded semaglutide and tirzepatide are a separate cash-pay category, priced independently by each provider as one all-in monthly amount. This route does not run through Medicare, so there is no prior-authorization wait, though it also means no Medicare copay assistance. Compounded medications are not FDA-approved as final products, and results may vary.
For a full breakdown of cash pricing, see our guide to whether insurance covers compounded GLP-1 medications.
How the numbers compare
The right comparison depends entirely on which door you can walk through.
| Your situation | Likely Medicare path | Approximate monthly cost |
|---|---|---|
| Qualify for GLP-1 Bridge | Wegovy or Zepbound KwikPen | $50 copay |
| Type 2 diabetes | Ozempic or Mounjaro via Part D | Plan copay, varies |
| Weight loss, do not qualify for Bridge | Not covered by Medicare | Brand self-pay from $299 to $699 a month depending on product and dose, as published by the manufacturers in August 2026 |
If you qualify for the Bridge program, $50 a month is almost certainly your best option. If you do not, price out both cash routes for your own dose: the manufacturers' self-pay programs have come down substantially in 2026, and compounded pricing is set per provider, so neither route wins automatically.
What to ask before you decide
Call your Part D plan and ask four questions:
- Am I eligible for the Medicare GLP-1 Bridge program, and what documentation does my provider need to submit?
- Does my plan cover any GLP-1 for a condition I have, such as type 2 diabetes or cardiovascular risk reduction?
- What is my actual copay or coinsurance on the covered product after any prior authorization?
- What is the total out-of-pocket cost over a full year, including the months the $50 copay does not count toward my out-of-pocket maximum?
The answers tell you whether the Medicare route or a cash route is the lower total cost for your situation.
The bottom line
Medicare finally covers GLP-1 medications for weight management in 2026, but only through a narrow, temporary program with specific eligibility, and only for Wegovy, the Zepbound KwikPen, and Foundayo at a $50 copay. Ozempic remains a diabetes-only product for Medicare, and compounded GLP-1 medications are not covered at all. If you qualify for the Bridge program, use it: nothing on the cash market competes with $50 a month for an FDA-approved product. If you do not qualify, price out the manufacturers' self-pay programs and the compounded cash route for your own situation before assuming you are stuck with list-price sticker shock.
To understand how compounding works as a category, read our compounded semaglutide guide.
This article is for educational purposes only and is not medical advice. Medicare coverage rules are complex, change over time, and depend on your specific plan; confirm details at Medicare.gov or with your Part D plan. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient meets United States Pharmacopeia (USP) standards. Always consult a licensed healthcare provider about your individual situation. Individual results may vary.
Frequently Asked Questions
Does Medicare cover Wegovy for weight loss in 2026?
As of July 1, 2026, Medicare can cover Wegovy for chronic weight management through a temporary program called the Medicare GLP-1 Bridge, but only if you qualify and only if you are not already getting a GLP-1 covered through your Part D plan. Outside that program, traditional Medicare Part D still does not cover any drug used solely for weight loss, because of a statutory exclusion that dates to the Medicare Modernization Act of 2003. Wegovy may also be covered separately when it is prescribed to reduce cardiovascular risk in beneficiaries with established heart disease. Coverage always depends on your specific plan's formulary and rules.
Does Medicare cover Ozempic?
Medicare Part D typically covers Ozempic when it is prescribed for type 2 diabetes, which is its primary FDA-approved use. Medicare does not cover Ozempic for weight loss, and importantly, Ozempic is NOT included in the new Medicare GLP-1 Bridge program that began July 1, 2026. If you have type 2 diabetes, your Part D plan may cover Ozempic subject to formulary placement and prior authorization. If you are seeking a GLP-1 purely for weight management, Ozempic is not the Medicare path.
What is the Medicare GLP-1 Bridge program?
The Medicare GLP-1 Bridge is a temporary federal demonstration program that began July 1, 2026 and is scheduled to run through December 31, 2027. It gives eligible Medicare Part D beneficiaries access to certain GLP-1 medications for chronic weight management at a $50 monthly copay. The covered drugs are Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo (tablet). Ozempic is not covered under this program for weight loss. The $50 copay does not count toward your Part D deductible or annual out-of-pocket maximum.
Who qualifies for the Medicare GLP-1 Bridge program?
Per the Medicare.gov fact sheet, you must meet all four requirements: have Medicare Part D drug coverage (a standalone drug plan or a Medicare health plan that includes drug coverage); not already be eligible to receive a GLP-1 drug through your Medicare drug plan; not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (for those conditions your plan may already cover a GLP-1); and be at least 18 with a BMI of 35 or higher, or a BMI of 30 or higher plus certain types of heart failure, hard-to-control high blood pressure, or chronic kidney disease at stage 3a or above, or a BMI of 27 or higher plus prediabetes or a history of heart attack, stroke, or blocked arteries in the legs or arms. Your doctor must also submit a form to get approval from Medicare before coverage starts.
Does Medicare cover compounded semaglutide or tirzepatide?
No. Medicare does not cover compounded GLP-1 medications, because compounded preparations are not FDA-approved final products and fall outside Part D formularies. The Medicare GLP-1 Bridge program covers only the specific brand-name products it names (Wegovy, Zepbound KwikPen, and Foundayo). If you do not qualify for the Bridge program or your plan denies coverage, compounded semaglutide or tirzepatide through a licensed telehealth provider is a cash-pay option outside Medicare entirely. Compounded medications are not FDA-approved as final products.
What are my options if Medicare will not cover my GLP-1?
If you do not qualify for the Medicare GLP-1 Bridge program, or you want a GLP-1 that Medicare does not cover for weight loss, you have a few routes. You can ask your provider whether a covered indication applies, such as type 2 diabetes or cardiovascular risk reduction. You can use the manufacturer's cash-pay pharmacy programs for brand-name drugs. Or you can consider compounded semaglutide or tirzepatide through a US-licensed telehealth provider, which is a separate cash-pay category priced independently by each provider. Compare the real out-of-pocket numbers for each route before deciding, including the manufacturers' own self-pay programs, which have come down substantially in 2026. Compounded medications are not FDA-approved as final products, and results may vary.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Medicare GLP-1 Bridge program page · Centers for Medicare & Medicaid Services
- 2.Fact sheet: Medicare GLP-1 Bridge, GLP-1 Drugs for $50 a Month (product 12234) · Medicare.gov
- 3.CMS launches Medicare GLP-1 Bridge, expanding access to GLP-1 medications · Centers for Medicare & Medicaid Services
- 4.Medicare GLP-1 Bridge: expectations and FAQs for Part D sponsors (June 10, 2026) · Centers for Medicare & Medicaid Services
Majesta Health medical content is written against primary sources (FDA labels, peer-reviewed trials, HHS and CDC publications) and passes a documented compliance review before publication. We are rolling out named physician review with US-licensed clinicians from our partner MD Integrations (MDI): each reviewed article will show the reviewing physician's name, NPI, and review date.
- US-licensed physicians affiliated with our clinical partner MD Integrations
- Practicing in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across states planned for launch through the MD Integrations Medical Services Organization (coverage varies by state and clinician licensure; see our states page)
- Dispensing pharmacy partner: Belmar Pharma Solutions; Majesta prescriptions are dispensed through Belmar's state-licensed 503A compounding pharmacy